CytoDyn Inc. Form 8-K (April 7, 2021)

Summary

Form 8-K current report of CytoDyn Inc., Commission File Number 000-49908, dated April 7, 2021 for an event of April 5, 2021. Its only disclosure, under Item 7.01, is that the last day of employment of Chief Scientific Officer Mahboob U. Rahman, M.D., Ph.D., with CytoDyn was April 5, 2021. The report gives no reason for the departure and is signed by Michael D. Mulholland, Chief Financial Officer.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 7, 2021 ( April 5, 2021 )

CytoDyn Inc.

(Exact name of registrant as specified in its charter)

Delaware | 000-49908 | 83-1887078
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)
1111 Main Street , Suite 660 Vancouver , Washington | 98660
(Address of principal executive offices) | (Zip Code)

Registrant’s telephone number, including area code: (360) 980-8524

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
None. | None. | None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 | Regulation FD Disclosure

The last day of employment of Chief Scientific Officer, Mahboob U. Rahman, M.D., Ph.D, with CytoDyn Inc. was April 5, 2021.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CYTODYN INC.
Dated: April 7, 2021 | By: | /s/ Michael D. Mulholland
Michael D. Mulholland
Chief Financial Officer

File and source

File

SEC_CYDY_8-K_filed2021-04-07_0001193125-21-108825.htm

Size

21,624 bytes

SHA-256

19937f84bbf147498725af68a4620fe9c5dbead1183f1d422b9dab268c31e4eb

Our copy

SEC_CYDY_8-K_filed2021-04-07_0001193125-21-108825.htm

Original

www.sec.gov